Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Clinical Informatics stories

Apr 29, 2026

Boehringer Ingelheim's Obesity Drug Shows 16.6% Weight Loss in Clinical Trial

Boehringer Ingelheim reported that its experimental obesity drug achieved 16.6% weight loss in clinical trials, marking another entrant in the competitive GLP-1 weight loss drug market.

Apr 29, 2026·1 source
00

Top claims

  • ▪Generic competition hit Novartis drugs like Entresto hard
  • ▪Boehringer Ingelheim's obesity drug showed 16.6% weight loss in a clinical trial
  • ▪Amgen insists that Tavneos is safe

Subtopics

Clinical evaluation1Clinical Trial Design & Evaluation1Clinical trials1Drug Approval and Clinical Trials1Drug Policy, Pricing & Approval1GLP-11GLP-1 / Weight-Loss Medications1GLP-1 drugs1GLP-1 medications1Lifestyle, Wellness and Nutrition1Obesity treatment1Weight loss medications & GLP-1 drugs1Weight management1

Related timelines

Congress

110 stories

Iran War

209 stories

Russia-Ukraine war

136 stories

Strait of Hormuz blockage

148 stories

Trump administration

161 stories